✦ LIBER ✦

Quality control measures for lowering the seroconversion rate of hemodialysis patients with hepatitis B or C virus

✍ Scribed by Yuan, Jing; Yang, Yi; Han, Fei; Zhang, Ping; Du, Xiao-Ying; Jiang, Hua; Chen, Jiang-Hua

Book ID: 118028656
Publisher: Zhejiang University School of Medicine, China
Year: 2012
Tongue: English
Weight: 107 KB
Volume: 11
Category: Article
ISSN: 1499-3872
DOI: 10.1016/s1499-3872(12)60164-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Shorter durations and lower doses of peg

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

✍ Y.-F. Liaw; J.-D. Jia; H.L.Y. Chan; K.H. Han; T. Tanwandee; W.L. Chuang; D.M. Ta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 2 views

As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared. HBeAg-p

984 Molecular profiles of drug response

984 Molecular profiles of drug response in HCV infected patients during the first 4 weeks of therapy for chronic hepatitis C virus with pegylated interferon containing regimens or albuferon™

✍ BALAN, V; NELSON, D; SULKOWSKI, M; ROSATI, M; BIRSE, C; PRAESTGAARD, J; OSBORN, 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Interferon alfa-2A (IFN) and amantadine

Interferon alfa-2A (IFN) and amantadine (A) or placebo (P) in IFN-naive patients with chronic hepatitis C (CHC): a doouble-blind, randomized, placebo-controlled trial (SASL 8): B Helbling, R Hermann, I Stamenic, University Hospital Zurich, Zurich Switzerland; F Viani, Jj Gonvers, University Hospital Lausanne, Lausanne Switzerland; Jf Dufour, J Reichen, University Hospital Bern, Bern Switzerland; G Cathomas, University Hospital Zurich, Zurich Switzerland; M Steuerwald, University Hospital Basel, Basel Switzerland; J Borovicka, Cantonal Hosp St Gallen, St Gallen Switzerland; El Renner, University Hospital Zurich, Zurich Switzerland; and the Investigators of the Swiss Assoc for the Study of the Liver (SASL), Switzerland

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB